ALMIRALL, S.A.

ALMIRALL, S.A. Overview

Company Headquarters: Maine, US

Founded: 1943

Workforce: 1,805

Company Working:

Almirall, S.A. is a pharmaceutical company. It engaged in research, development, manufacturing, and commercialization of medicines and licensed products. The company offers some of the major brands in the market, including the Ciclopoli franchise, Solaraze, Decoderm franchise, Skilarence, among others. The company’s products focus on treating respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), autoimmune diseases including rheumatoid arthritis and multiple sclerosis, dermatological diseases including psoriasis, eczema, acne, and other skin infections, and gastrointestinal diseases including irritable bowel syndrome with constipation.

Strategy

Almirall, S.A focuses on increasing its footprints globally by establishing its manufacturing, research and development, and commercial operations in many regions across the world. To do this, the company is highly involved in the strategic agreement or partnership with other firms. The company aims to develop and grow its R&D pipeline to address highly underserved diseases within oncodermatology and immunodermatology.

Company Snapshot

$854.1M

Revenue

1,805

Employees

1943

Founded

Maine, US

Headquarters

SWOT Analysis

Strengths

Global presence
Strong R&D
Skilled workforce
Wide distribution network
Large consumer base
High consumer satisfaction

Weaknesses

Quality of products
Price of products
Supply demand gap due to poor forecasting abilities
Major dependency on the European market for revenue generation

Opportunities

Growth in dermatology and medical aesthetics areas
Leading dermatology therapy
Entering emerging markets
Collaboration with the public sector institutes
Targeting new customers through online channels

Threats

Government regulations
Climate change risk
Strict government regulations
Fluctuations in foreign exchange rates

Key Developments

Date	Approach	Development
December 2017	Partnership	Almirall S.A. and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.
February 2020	Agreement	Almirall signed a license agreement with Paratek Pharmaceuticals, Inc. for the development of Seysara in China.
January 2019	Product Launch	Almirall announced the launch of Seysara, a novel tetracycline-derived oral antibiotic and the first to be developed specifically for the treatment of acne. The product is commercially launched in the US market.
October 2018	Approval	Almirall received the FDA approval for Seysara (sarecycline) an oral antibiotic for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.
September 2018	Acquisition	Almirall acquired Allergan's Medical Dermatology unit in the US. The acquisition enhanced the former’s dermatology portfolio.

Product Offering

ALMIRALL, S.A.
- Aknemycin
- Akneroxid
- Actikerall
- Aknenormin
- Amciderm
- Aknemycin Plus
- Aknosan
- Others
- Acne Treatment

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.